Subscribe to RSS
Download PDF
DOI: 10.4103/ajm.AJM_127_17
Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review
Financial support and sponsorship Nil.
Abstract
Immune-related adverse events have been reported in patients treated with anti-programmed death-1 receptor drugs such as nivolumab. We present a case of a new-onset seronegative rheumatoid arthritis in a patient with metastatic melanoma treated with nivolumab.
Keywords
Immune-related adverse event - immunotherapy - inflammatory arthropathy - nivolumab - rheumatoid arthritisPublication History
Article published online:
12 August 2021
© 2018. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
-
References
- 1 Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. et al. PD-1/PD-L1 blockade in cancer treatment: Perspectives and issues. Int J Clin Oncol 2016; 21: 462-73
- 2 Medina PJ, Adams VR. PD-1 pathway inhibitors: Immuno-oncology agents for restoring antitumor immune responses. Pharmacotherapy 2016; 36: 317-34
- 3 Guibert N, Mazières J. Nivolumab for treating non-small cell lung cancer. Expert Opin Biol Ther 2015; 15: 1789-97
- 4 Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015; 23: 32-8
- 5 Alexander W. The checkpoint immunotherapy revolution: What started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge. P T 2016;41:185-91.
- 6 Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236: 219-42
- 7 Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I. et al. Trial watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015; 4: e1008814
- 8 Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V. et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 2016; 45: 7-18
- 9 Kong BY, Micklethwaite KP, Swaminathan S, Kefford RF, Carlino MS. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res 2016; 26: 202-4
- 10 Syrigos K, Tsagouli S, Grapsa D. Nivolumab-induced recurrence of rheumatoid arthritis in a patient with advanced non-small cell lung cancer: A Case report. Ann Intern Med 2016; 165: 894-5
- 11 Raptopoulou AP, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M. et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum 2010; 62: 1870-80
- 12 Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y. et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016; 375: 1749-55
- 13 Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC. et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016; 68: 1-25